Azido-DAPY UV Crosslinking for Irreversible Reverse Transcriptase Inactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HIV compounds that inhibit reverse transcriptase activity are reversible, allowing the enzyme to escape inactivation, necessitating the development of compounds that can permanently inactivate reverse transcriptase to prevent viral replication.
Innovation Solution
Azido-diarylpyrimidine compounds, derived from DAPY structures like dapivirine and etravirine, are used in conjunction with UV light to form an irreversible covalent bond with reverse transcriptase, ensuring permanent inactivation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If reversible anti-HIV compounds are used to inhibit reverse transcriptase, then the enzyme activity is suppressed, but the enzyme can escape inactivation and resume function
Solution Approach 1:
The invention changes the chemical bonding parameter from reversible to irreversible covalent bonding. The photoreactive group forms permanent covalent bonds with reverse transcriptase upon light activation, fundamentally altering the interaction parameter from transient to permanent, thereby resolving the contradiction between suppression effectiveness and inactivation persistence
Solution Approach 2:
The invention replaces the reversible competitive inhibition mechanism with an irreversible photochemical crosslinking mechanism. Instead of relying on continuous presence of the inhibitor compound, the system uses light-activated covalent bonding to permanently inactivate the enzyme, substituting a reversible chemical interaction with an irreversible one
2Reliability
If irreversible covalent bonding is used to inactivate reverse transcriptase, then permanent inactivation is achieved, but the complexity of the compound structure increases
Solution Approach 1:
The invention creates a composite molecular structure combining an anti-HIV active compound with a photoreactive group. This composite structure integrates two functional components: the original compound that binds to reverse transcriptase and the photoreactive group that forms covalent bonds upon light exposure, achieving permanent inactivation while maintaining the compound's core functionality
Solution Approach 2:
The invention merges two distinct functional elements into a single unified compound: the anti-HIV active moiety and the photoreactive group. This merging allows the compound to perform dual functions - specific binding to reverse transcriptase and irreversible crosslinking - thereby achieving permanent inactivation without requiring separate components or complex delivery systems
3Reliability
If photoreactive groups are added to anti-HIV compounds, then irreversible inactivation is achieved, but the synthesis and purification processes become more difficult
Solution Approach 1:
The photoreactive group is pre-installed on the anti-HIV compound during the synthesis phase, before the compound needs to exert its biological effect. This preliminary incorporation of the photoreactive functionality allows for straightforward synthesis using standard organic chemistry techniques, avoiding the need for complex post-synthesis modifications or multi-step activation procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The azido-diarylpyrimidine compounds effectively produce non-infectious viral particles that elicit a protective immune response and can be used as microbicides to prevent HIV transmission, offering a solution for irreversible inactivation of reverse transcriptase and enhanced immunogenicity.
Implementation Method 1
Azido-diarylpyrimidine compounds, derived from DAPY structures like dapivirine and etravirine, are used in conjunction with UV light to form an irreversible covalent bond with reverse transcriptase
Data Source
AI summary
Azido-diarylpyrimidine (azido-DAPY) compounds, and compositions containing such compounds, are provided. In addition, methods of using azido-diarylpyrimidines to inactivate reverse transcriptases, prepare inactivated viruses, and treat or prevent viral infections are also provided.